ESCALATED BEACOPP

INDICATION: Advanced Hodgkin's lymphoma

Prior to a course of treatment

- Assess cardiac function by history & exam, ECG and CXR. If there is evidence of cardiac disease or risk factors, prior anthracyclines or patient > 70yrs perform a MUGA scan. Inform consultant.
- Check recent U&Es, creat, LFTs see dose modification and discus with consultant if abnormal
- Check FBC. Patient should have adequate bone marrow reserve, i.e Neutrophils >1.5, platelets >80 unless cytopaenia is due to disease, e.g marrow infiltration, splenomegaly
- Consider PICC or Hickman line if venous access is poor.
- If appropriate discuss possibility of pregnancy with female patients and need for contraception with both male and female patients. Discuss risk of infertility offer semen cryopreservation to male patients
- · Written consent for course

Prior to each cycle

- Medical review of fitness for chemotherapy exclude active infection, major changes in organ function
- Check FBC, U&Es, creat, LFTs neutrophils must be > 1.5, platelets > 80 see dose modifications & algorithm below

Cyclophosphamide	1250mg/m ²	IV (see protocol for fluids & mesna)	day 1
Doxorubicin	35mg/m ²	IV bolus	day 1
Etoposide	200mg/m ²	IV in 1.0L N saline over 1 hr	days 1-3
Procarbazine #	100mg/m ² od	РО	days 1-7
Prednisolone	40mg/m ²	РО	days 1-14
Vincristine	1.4mg/m ² *	IV in 50ml N saline over 5 minutes	day 8
Bleomycin	10000U/m ²	IV bolus	day 8
GCSF	5mcg/kg	SC od	from day 9 of each cycle
* maximum dose of vincristine is 2mg		[#] 50mg capsules	

GCSF PROPHYLAXIS IS MANDATORY WITH ESCALATED BEACOPP. Start on day 9 and continue until WBC has passed through the nadir and has been > 1.0 for 3 days. The nadir is expected at day 11-12. When neuts are < 1.0 FBC must be checked at least every second day.

Repeat cycle every 21 days for up to 6 cycles

NB: Patient must be advised to avoid alcohol while taking procarbazine

Prophylaxis for acute emesis

5HT antagonist

5HT antagonist and metoclopramide

5HT antagonist and metoclopramide

Allopurinol 300mg od days 1-14 of cycle 1

Fluconazole 50mg od days 1-14 of each cycle

Nystatin 1ml qds & Corsodyl 10ml qds mouthwash

Cotrimoxazole 480mg od throughout treatment plus 2 weeks

Administration of mesna & IV fluids is mandatory with BEACOPP when cyclophosphamide is >1.0g/m²

Day 1 T - 1 hour N Saline 0.5L over 1 hr

T - 15mins Mesna 1.0g/m² IV in 100ml N saline over 15mins T = 0 Ondansetron 8mg IV + dexamethasone 8mg IV

CYCLOPHOSPHAMIDE 1250mg/m² in 1.0L N saline over 1hr

T + 1 hours N saline 1.0L over 3hrs

T + 4 hours Mesna 1.0g/m² IV in 100ml N saline over 15mins

· Check urinalysis for haematuria with each urine

If not vomiting allow home with ondansetron 8mg bd for 3 days

Instruct patient to drink at least 3L/day fluid over next 48hrs

• Instruct patient to return to ward if vomiting, frank haematuria, dysuria or fever

If frank haematuria give additional mesna 1g, IV fluids and inform consultant

Dose modification for hepatotoxicity (unless due to lymphoma)

• Bilirubin <1.5 x upper limit of normal 100% dose doxorubicin

Bilirubin 1.5 - 3 x upper limit of normal
 75% dose doxorubicin

Bilirubin > 3 x upper limit of normal
 Reconsider whether further escalated BEACOPP is

appropriate - discuss with consultant

Dose modification for renal dysfunction (unless due to lymphoma)

Escalated BEACOPP may not be appropriate if serum creatinine > 150μmol/l or creatinine clearance < 40ml/min – discuss with consultant

Dose modifications for vincristine neurotoxicity

 Grade 2 motor (mild <u>objective</u> weakness interfering with function but not with activities of daily living) or grade 3 sensory (sensory loss or paraesthesia interfering with activities of daily living) toxicity Reduce vincristine dose to 1mg

Neurological toxicity increases despite dose reduction.

Stop vincristine. Consider vinblastine 4mg/m² – *discuss* with consultant

Modification for haemorrhagic cystitis

 If there is gross haematuria passing clots, requiring instrumentation or transfusion Stop cyclophosphamide – further escalated BEACOPP inappropriate – *inform consultant*

• Significant microscopic or frank haematuria

Give additional mesna 1g IV

For bleomycin pulmonary toxicity

• If patient develops persistent unexplained dyspnoea or non-productive cough – stop bleomycin, perform chest X-ray and *discuss with consultant*. If there is clinical or radiological evidence of pulmonary fibrosis or transfer factor reduced <50% bleomycin should be permanently stopped.

For cardiotoxicity

• If symptoms or signs of cardiac failure develop, the LVEF should be measured by MUGA scan. Discontinue BEACOPP if LVEF <50%. *Inform consultant*.

For procarbazine intolerance or unavailability

Replace with chlorambucil 6mg/m² (max.10mg) od PO for 7 days


Dose modification for haematological toxicity (unless due to disease)

 Depending on neutrophil and platelet count prior to each cycle dose reductions to steps 1, 2 or baseline BEACOPP may be indicated. Follow algorithm below – dose reduction steps are:

	Full dose	Step 1	Step 2	<u>Baseline</u>	
Cyclophosphamide	1250mg/m ²	1100mg/m ²	950mg/m ²	650mg/m ²	Day 1
Doxorubicin	35mg/m ²	35mg/m ²	35mg/m ²	25mg/m ²	Day 1
Etoposide	200mg/m ²	175mg/m ²	150mg/m ²	100mg/m ²	Days 1-3
Procarbazine	100mg/m ²	100mg/m ²	100mg/m ²	100mg/m ²	Days 1-7
Prednisolone	40mg/m ²	40mg/m ²	40mg/m ²	40mg/m ²	Days 1-14
Vincristine	1.4mg/m ² *	1.4mg/m ² *	1.4mg/m ² *	1.4mg/m ² *	Day 8
Bleomycin	10000U/m ²	10000U/m ²	10000U/m ²	10000U/m ²	day 8
GCSF	5mcg/kg	5mcg/kg	5mcg/kg	5mcg/kg	from day 9 of
* max. 2mg					each cycle

BEACOPP Toxicities			
Neutropenic sepsis & thrombocytopenia	Nausea (moderate) – but severe with alcohol & procarbazine		
Mucositis	Amenorrhoea & infertility (offer semen cryopreservation)		
Alopecia	Interstitial pneumonitis & (late) pulmonary fibrosis		
Cardiac arrythmias & cardiomyopathy	Anaphylaxis (rarely) & febrile reactions with bleomycin (maybe several hours later)		
Peripheral neuropathy	Mucocutaneous reactions & hyperpigmentation (bleomycin)		
Second malignancies (late)	Photosensitivity (procarbazine)		
Hyperglycaemia	Autonomic neuropathy – commonly constipation, ileus		
Hypotension, chest pain, dyspnoea, flushing and bronchospasm (etoposide)	Haemorhagic cystitis		

Escalated BEACOPP modifications for haematological toxicity



....etc for further cycles, i.e......

- if a dose reduction is indicated during the present cycle & it was reduced in the previous cycle, reduce to baseline BEACOPP immediately
- if the dose was reduced by one step in an earlier cycle (but not the previous cycle) and a further dose reduction is indicated in the present cycle, reduce dose by one more step
- once dose reduced never dose increase again

LSCCN HAEMATOLOGY PROTOCOLS

Written by Dr MP Macheta, Consultant Haematologist

Date January 2014

Review date January 2016